This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
by Zacks Equity Research
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
BMYPositive Net Change JNJNegative Net Change PTGXPositive Net Change ARVNPositive Net Change
pharmaceuticals
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
by Zacks Equity Research
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
AZNNegative Net Change NVSPositive Net Change JNJNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
by Zacks Equity Research
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
RHHBYPositive Net Change BAYRYNegative Net Change SRPTPositive Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
by Sundeep Ganoria
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
BIIBPositive Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Best Value Stocks to Buy for July 22nd
by Zacks Equity Research
OPRT, BAYRY and SHG made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 22, 2025.
BAYRYNegative Net Change SHGNegative Net Change OPRTNegative Net Change
finance pharmaceuticals
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
by Anirudha Bhagat
Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
ORNNegative Net Change CPRXPositive Net Change BWAYNegative Net Change GAMBPositive Net Change
construction medical medical-devices pharmaceuticals
New Strong Buy Stocks for July 22nd
by Zacks Equity Research
BTG, PGR, BAYRY, BCH and LNW have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2025.
BAYRYNegative Net Change PGRNegative Net Change BCHPositive Net Change BTGPositive Net Change LNWPositive Net Change
consumer-discretionary finance gold insurance pharmaceuticals
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
by Zacks Equity Research
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
RHHBYPositive Net Change BAYRYNegative Net Change SRPTPositive Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
by Zacks Equity Research
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
JNJNegative Net Change BAYRYNegative Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
by Kinjel Shah
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
JNJNegative Net Change AMGNPositive Net Change TEVAPositive Net Change KVUENegative Net Change
pharmaceuticals
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
by Kinjel Shah
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
AZNNegative Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
SNYPositive Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
by Zacks Equity Research
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
by Ahan Chakraborty
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
by Zacks Equity Research
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
AZNNegative Net Change PRTAPositive Net Change AGENPositive Net Change AKROPositive Net Change
biotechs medical pharmaceuticals
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
by Zacks Equity Research
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
BAYRYNegative Net Change AGENPositive Net Change MDGLPositive Net Change VRNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
by Ahan Chakraborty
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.
SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
by Sweta Killa
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
JNJNegative Net Change XLVPositive Net Change IYHPositive Net Change IHEPositive Net Change PPHNegative Net Change FTXHPositive Net Change
earnings etfs pharmaceuticals
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
by Zacks Equity Research
Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.
RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change
biofuels gene-editing gene-therapy medical pharmaceuticals
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
by Kinjel Shah
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
NVONegative Net Change MRKPositive Net Change LLYNegative Net Change
pharmaceuticals
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
by Zacks Equity Research
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
NVSPositive Net Change RHHBYPositive Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology earnings medical pharmaceuticals
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
by Zacks Equity Research
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
SNYPositive Net Change APLSNegative Net Change ARVNPositive Net Change AKROPositive Net Change
pharmaceuticals
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
by Zacks Equity Research
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
JNJNegative Net Change AMGNPositive Net Change TEVAPositive Net Change KVUENegative Net Change
pharmaceuticals
Strong Q2 Earnings, Cooling PPI Lead Pre-Markets Higher
by Mark Vickery
Headline PPI for June, month over month, reached 0.0% -- lower than the +0.2% expected and 30 bps below May.
GSNegative Net Change BACNegative Net Change MSNegative Net Change JNJNegative Net Change
banking earnings inflation pharmaceuticals
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
by Ahan Chakraborty
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
SDGRPositive Net Change RLAYPositive Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals